These experiments as a whole confirmed the non-autonomous effects of Omomyc on the tumor microenvironment, while also reinforcing the notion of its safety in long-term systemic treatments, and expanded the list of tumor types as candidate for Myc inhibition treatment, regardless of their tissue of origin or driving mutation. Here, MYC is linked to neoplasm.